Pulling SEC filings + quote and writing the call…
KALV
KalVista Pharmaceuticals, Inc.
Last earnings +4.1% on 2026-03-25
$27.00▲ +107.06%
over 1Y
L $10.76EODHDH $27.00
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today—
1W+0.2%
1M+0.7%
3M+59.4%
YTD+74.6%
1Y+107.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Revenue grew 495.7% YoY; but unprofitable (net margin -366.9%).
KalVista Pharmaceuticals, Inc. shows $50.0M in FY2024 revenue (+495.7% YoY), a -366.9% net margin, and -192.3% ROE.
Sources: SEC EDGAR (CIK 0001348911, latest 10-Q filed 2026-05-14) · as of 6/22/2026, 1:53:17 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.